This is the first analysis of a cohort of patients with EGFRm NSCLC receiving 1G/2G EGFR TKIs in 1L therapy from four CEE countries, and it offers a comprehensive overview of treatment patterns and clinical outcomes. Here, EGFR is linked to non-small cell lung carcinoma.